United Skies Unfriendly After Treprostinil Flunks Oral Exam
By Randy Osborne
Wednesday, October 24, 2012
United Therapeutics Inc. will stay in hunker-down mode for the next few months, as the company works to puzzle out exactly what the FDA wants, in the wake of a complete response letter that found the data package unacceptable in the new drug application for oral treprostinil in pulmonary arterial hypertension (PAH).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.